N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
Conditions
Gambling | Tobacco Use Disorder
What is the purpose of this trial?
The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.
Participation Guidelines
- Age:
- 18 Years - 75 Years
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- National Institute on Drug Abuse (NIDA)
University of Minnesota - Clinical and Translational Science Institute
Yale University - Dates:
- September 2009
- Last Updated:
- February 23, 2012
- Study HIC#:
- 0909005714
Clinicaltrials.gov ID: NCT00967005
